ArticleCureus2026
Immunohistochemical Evaluation of p53 and Its Association With Prognostic Parameters in Breast Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background P53 is a tumour suppressor gene that is commonly altered in breast cancer, potentially affecting tumour behaviour and prognosis. However, the clinicopathological and molecular associations vary across studies. Hence, the present study aims to evaluate p53 positivity and its association with clinicopathological parameters and molecular subtypes in invasive breast carcinoma. Aims and objectives To evaluate p53 positivity in invasive breast carcinoma and analyse its association with key clinicopathological parameters. Methods A cross-sectional observational study was undertaken in the pathology department of a tertiary care hospital. Immunohistochemistry was used to measure p53 expression, which was then linked with clinicopathological features like tumour size, histological grade, lymph node status, lymphovascular invasion, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status, Ki-67 proliferation index, and molecular subtype. Statistical analysis was done using SPSS software. Chi-square and Fisher's exact tests were used for correlation analysis, and p-values <0.05 were considered significant. Results P53 positivity was detected in 57.5% of the cases. P53 positivity was shown to be significantly associated with greater tumour size (p=0.029) and a high Ki-67 index (p=0.042) whereas histological grade, lymph nodal metastasis, lymphovascular invasion or hormone receptor status did not show statistical significance. Although hormone receptor-negative tumours showed more frequent p53 positivity status compared to a negative status, the results were not significant (p=0.052). P53 positivity was most frequent in aggressive molecular subtypes of tumours, like HER2-enriched (77.8%) and luminal B (75%) tumours. Conclusion P53 expression is associated with aggressive clinicopathological features like large tumour size, high Ki-67 index and the HER2-enriched subtype, suggesting its role in tumour progression and aggressiveness. Further, large multicentric studies with survival analysis are needed to confirm its clinical validity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.